A randomized phase III trial of gemcitabine and docetaxel versus gemcitabine and paclitaxel in patients with metastatic breast cancer: a comparison of different schedules.

Trial Profile

A randomized phase III trial of gemcitabine and docetaxel versus gemcitabine and paclitaxel in patients with metastatic breast cancer: a comparison of different schedules.

Discontinued
Phase of Trial: Phase III

Latest Information Update: 28 Mar 2013

At a glance

  • Drugs Docetaxel; Gemcitabine; Paclitaxel
  • Indications Advanced breast cancer
  • Focus Therapeutic Use
  • Most Recent Events

    • 05 Jun 2012 Status changed from completed to discontinued.
    • 05 Jun 2012 Results presented at the 48th Annual Meeting of the American Society of Clinical Oncology.
    • 03 Sep 2010 Actual end date (Aug 2010) added as reported by ClinicalTrials.gov.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top